Mubadala enters into a definitive deal to acquire KELIX bio
The photo has been used for illustrative purposes.
KELIX bio was incepted in November 2020, and has since, acquired manufacturing businesses in India, Egypt, Malta and Morocco successfully commercialising a broad range of both oral and injectable formulations covering diverse therapy areas including diabetes, oncology, cardiology, and central nervous systems.
The acquisition is set to boost the UAE’s global standing in life sciences. With Kelix bio specialising in relevant therapy areas and a leadership team experienced in successful buy-and-build strategies globally, the move aligns with Mubadala’s goal to position the UAE prominently in the global life sciences sector.
Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, said, “In line with our role as a responsible investor, today’s acquisition is testament to the role Mubadala continues to play in accelerating the nation’s economic diversification through our portfolio companies and national champions.”
He added: “This partnership marks a key milestone in further advancing Mubadala’s position in the life sciences sector, to deliver important long-term socio-economic returns for our nation including improved healthcare, drug security, job creation and GDP impact.”
Ismail Ali Abdulla, Head of UAE Clusters, Mubadala’s UAE Investments Platform, said, “At Mubadala, we are deeply committed to enhancing the well-being of our communities through strategic investments that address critical health care needs. By amplifying our domestic capabilities in producing essential medications via Kelix bio, our goal is to significantly empower the UAE’s healthcare infrastructure, ensuring wider access to life-saving treatments for all citizens. This investment is a testament to our dedication as a responsible investor, emphasising our commitment to investing in solutions that address the world’s most pressing challenges.”
WAM
